"Gabexate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
| Descriptor ID |
D016670
|
| MeSH Number(s) |
D02.078.370.380
|
| Concept/Terms |
Gabexate Methanesulfonate- Gabexate Methanesulfonate
- Methanesulfonate, Gabexate
- Gabexate Mesylate
- Mesylate, Gabexate
- Gabexate Mesilate
- Mesilate, Gabexate
|
Below are MeSH descriptors whose meaning is more general than "Gabexate".
Below are MeSH descriptors whose meaning is more specific than "Gabexate".
This graph shows the total number of publications written about "Gabexate" by people in this website by year, and whether "Gabexate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 0 | 5 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Gabexate" by people in Profiles.
-
Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19. Eur J Pharmacol. 2021 Jan 05; 890:173720.
-
Molecular Insights into Human Transmembrane Protease Serine-2 (TMPS2) Inhibitors against SARS-CoV2: Homology Modelling, Molecular Dynamics, and Docking Studies. Molecules. 2020 Oct 29; 25(21).
-
The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer. Future Oncol. 2020 Sep; 16(27):2029-2033.
-
Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. Rev Med Virol. 2020 09; 30(5):e2136.
-
The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner. Viruses. 2020 06 10; 12(6).
-
Potential therapeutic targets and promising drugs for combating SARS-CoV-2. Br J Pharmacol. 2020 07; 177(14):3147-3161.
-
Comprehensive analysis of drugs to treat SARS-CoV-2 infection: Mechanistic insights into current COVID-19 therapies (Review). Int J Mol Med. 2020 Aug; 46(2):467-488.
-
Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2). Molecules. 2020 May 12; 25(10).
-
Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication. Tohoku J Exp Med. 2020 05; 251(1):27-30.
-
Camostat mesilate therapy for COVID-19. Intern Emerg Med. 2020 Nov; 15(8):1577-1578.